Best in Biotech 15 Sep 2023 Five latest advancements in NASH research …seemed to be well-tolerated among the participants, with mild gastrointestinal issues being the most common side effect. But, no serious drug-related adverse events were reported. “We’re highly encouraged by the… September 15, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 May 2025 Interleukin therapeutics: 9 companies to follow in 2025 …natural killer (NK) cells and T lymphocytes. However, its clinical application has been limited due to the presence of IL-18 binding protein (IL-18BP), a naturally-occurring inhibitor that prevents IL-18 from… May 27, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 4 Jun 2025 The biggest biotech funding rounds in May 2025 …Public biotech funding by therapeutic subsector Mirroring the events of last month’s private biotech funding, oncology companies also performed the best in the public fundraising landscape in May, raising $317.25… June 4, 2025 - 4 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2023 Cancer Genomics: Technological innovation set to fuel research breakthroughs …splicing events, including 35 significantly associated with patient survival. Such technology edges us closer to the goal of diagnosing at the earliest possible stage and informing precision oncology treatment decisions…. February 1, 2023 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2023 Promising results from phase 3 prostate cancer study …of each of the medicines. The most common adverse events in those treated with XTANDI plus leuprolide were fatigue, hot flush, and arthralgia and in those treated with XTANDI monotherapy… May 5, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2024 CRISPR-Cas13: how does the technology compare to its famous Cas9 cousin? …cleave ssRNA, is an extremely welcome proposition. RNA viruses account for many human diseases and pandemic events but are often not targetable by traditional therapeutic modalities. Here are a few… June 27, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 17 Aug 2022 TurtleTree produces first precision fermentation sustainable lactoferrin …commercial launch in 2023. TurtleTree chief strategist, Max Rye, said: “Looking at recent events like the infant formula shortage in the US and the disruptions in food supply arising from… August 17, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Positive results from study of drug to treat patients with breast cancer published …safety. Overall, pruxelutamide demonstrated a good safety profile. The most common grade 3 or 4 adverse events were aspartate transaminase (AST) increase (8.9%) and γ-glutamyltransferase increase (8.9%). No treatment-related deaths… September 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 11 Nov 2022 Prurigo nodularis treatment recommended for EU approval …results of the trial were generally consistent with the known safety profile of Dupixent in its approved dermatology indication. Adverse events more commonly observed with Dupixent compared to placebo included… November 11, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Oct 2025 Five latest advancements in Tourette’s syndrome research …Tourette’s. It reduced tic-like movements and disrupted a phenomenon known as prepulse inhibition – when a weaker stimulus prevents a reaction to a stronger stimulus through a startle reflex – involved in Tourette syndrome. It will be a… October 20, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 26 Oct 2023 Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials …events,” including brain bleeding. Cassava Sciences accused of scientific misconduct in latest Alzheimer’s drug controversy Just this month, Cassava Sciences was the latest company to come under fire for its… October 26, 2023 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 9 Aug 2024 The therapeutic potential of circular RNA: Could it soon trump mRNA technology? …effective as single doses, and patients could suffer fewer adverse events since lower quantities of the active ingredient would be needed. Another way that circular RNA could be superior to… August 9, 2024 - 5 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email